> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Accepts NDA for Rhopressa for Glaucoma Pressure
- URL: https://www.fdaweb.com/fda-accepts-nda-for-rhopressa-for-glaucoma-pressure/
- Published: 2017-05-15T12:00:00.000Z
- Updated: 2026-09-14T22:23:33.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5138694

FDA has accepted for review an Aerie Pharmaceuticals NDA for Rhopressa (netarsudil ophthalmic solution) 0.02%, indicated for treating elevated intraocular pressure (IOP) in glaucoma. The agency has set a user fee review target date of 2/28/2018, and it has told the firm to expect an advisory committee review.

  
The company describes the product as a novel eye drop that targets the trabecular meshwork, the eye’s primary fluid drain and the diseased tissue responsible for elevated IOP in glaucoma. “Preclinical and clinical studies have also demonstrated that Rhopressa lowers episcleral venous pressure, which contributes approximately half of IOP in healthy subjects,” it says. “Further, based on Aerie’s preclinical studies, Rhopressa may provide an additional mechanism that reduces fluid production in the eye and therefore lowers IOP.”